
Sacituzumab Govitecan Shows Consistent Efficacy in Real-World mTNBC
Sacituzumab govitecan-hziy (Trodelvy) showed similar efficacy and safety in real-world patients with metastatic triple-negative breast cancer (mTNBC) who received the agent in the second- or later-line setting when compared with that seen in prior clinical …